



BRIAN SANDOVAL
Governor

STATE OF NEVADA
DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 E. William Street, Suite 101
Carson City, Nevada 89701
(775) 684-3676 • Fax (775) 687-3893

RICHARD WHITLEY, MS
Director

MARTA JENSEN
Acting Administrator

NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD

AGENDA

Date of Posting: December 18, 2015

Date of Meeting: Thursday, January 28, 2016 at 5:15 PM

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board (DUR)

Place of Meeting: Best Western Plus Airport Plaza Hotel
1981 Terminal Way
Reno, NV 89502

Webinar Pre-Registration **Must Pre-Register**

<https://catamaranrx.webex.com/catamaranrx/onstage/g.php?MTID=efe12bc126e479bc3af7688a13d9d10d1>

Once you have registered for the meeting, you will receive an email message confirming your registration. This message will provide the information that you need to join the meeting.

Event Number: 744 153 821

Click “Join Now”

Follow the instructions that appear on your screen to join the audio portion of the meeting. Audio will be transmitted over the internet. No phone number is required.

AGENDA

1. Call to Order and Roll Call

2. Public Comment on Any Matter on the Agenda

3. Administrative

- a. **For Possible Action:** Review and Approve Meeting Minutes from November 5, 2015.
- b. Status Update by DHCFP
Federal Upper Limit (FUL) pricing.

4. Board Action

- a. **For Possible Action:** Discussion and proposed adoption of prior authorization criteria for all prescription drugs for Hospice Program recipients over the age of 20.
 - i. Public comment on the Hospice Program Covered Drugs
 - ii. Discussion by the Board and review of utilization data and current policy
 - iii. Possible adoption of updated Hospice drug coverage policy and criteria

5. Clinical Presentations

- a. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria for medications used in the treatment of Hepatitis C.
 - i. Public comment on adoption of policy.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Possible adoption of prior authorization criteria/policy.
- b. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for tasimelteon (Hetlioz®).
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.
- c. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors.
 - i. Public Comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by the Board and review of utilization data.

- iv. Proposed adoption of updated prior authorization criteria
- d. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for colchicine (Colcrys®)
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.
- e. **For Possible Action:** Discussion and possible adoption of updated prior authorization criteria for the for medications used for the treatment ADD/ADHD.
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.
- f. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for levalbuterol (Xopenex®)
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.
- g. **For Possible Action:** Discussion and possible adoption of prior authorization criteria for naltrexone (Vivitrol®)
 - i. Public comment on proposed clinical prior authorization criteria.
 - ii. Presentation of utilization and clinical information.
 - iii. Discussion by Board and review of utilization data.
 - iv. Proposed adoption of updated prior authorization criteria.

6. Public Comment on any DUR Board Requested Report

7. DUR Board Requested Reports

- a. Cumulative acetaminophen report
 - i. Discussion by the Board and review of utilization data.
- b. Anticonvulsant utilization trending report
 - i. Discussion by the Board and review of utilization data.
- c. Naloxone utilization
 - i. Discussion by the Board and review of utilization data.

8. Public Comment on any Standard DUR Report

9. Standard DUR Reports

- a. Review of Prescribing/Program Trends.
 - i. Top 10 Therapeutic Classes for Q2 2015, Q3 2015 and Q4 2015 (by Payment and by Claims).
 - ii. Top 50 Drugs of Q2 2015, Q3 2015 and Q4 2015 (by Payment and by Claims).
- b. Concurrent Drug Utilization Review (ProDUR)
 - i. Review of Q2 2015, Q3 2015 and Q4 2015.
 - ii. Review of Top Encounters by Problem Type.
- c. Retrospective Drug Utilization Review (RetroDUR)
 - i. Status of previous quarter.
 - ii. Status of current quarter.
 - iii. Review and discussion of responses.

7. Closing Discussion

- a. Public comments on any subject.
- b. Date and location of the next meeting.
 - i. Discussion of the time of the next meeting.
- c. Adjournment.

PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and announced at this meeting by the chairperson. All public comment may be limited to 5 minutes.

This notice and agenda have been posted at <http://dhcfnv.gov> and <http://notice.nv.gov>

Notice of this meeting will be available on or after the date of this notice at the DHCFP Web site www.dhcfp.nv.gov, Carson City Central office and Las Vegas DHCFP. The agenda posting of this meeting can be viewed at the following locations: Nevada State

December 18, 2015

Page 5

Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the meeting materials will be mailed to you. Requests and/or written comments may be sent to Lezlie Mayville at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701, at least 3 days before the public hearing.

All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.

Note: We are pleased to make accommodations for members of the public who have disabilities and wish to attend the meeting. If special arrangements are necessary, notify the Division of Health Care Financing and Policy as soon as possible and at least ten days in advance of the meeting, by e-mail at lezlie.mayville@dncfp.nv.gov in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Lezlie Mayville at (775) 684-3681.